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Lung cancer remains the leading cause of cancer-related death in 
both men and women in the United States (1). Because prognosis 
is related to stage, there has been long-standing interest in detect-
ing lung cancer while the disease is still asymptomatic, in the hope 
that it will be more responsive to treatment. Several observational 
studies have shown that screening by reduced dose helical com-
puted tomography can detect smaller sized and earlier stage lung 
cancers than can be detected by symptoms or by screening chest 
radiographs (2–9). However, it is not known whether the increased 
detection of apparently early-stage lung cancers by computerized 
tomography screening ultimately results in decreased lung cancer–
specific mortality. To answer this critical question, the National 
Lung Screening Trial (NLST) was launched on September 18, 
2002.  The  NLST,  a  randomized  controlled  trial  designed  to   
determine  whether  screening  with  computerized  tomography 
could reduce lung cancer mortality relative to single-view chest 
radiograph screening, is a multi-institutional trial funded by the 
US National Cancer Institute (NCI). It is conducted through a 
collaboration of the NCI Division of Cancer Prevention, which 
administers the component of NLST known as the Lung Screening 
Study  through  a  contract  mechanism,  and  the  NCI  Cancer 
Imaging Program, Division of Cancer Treatment and Diagnosis, 
which funds the component administered by the American College 
of  Radiology  Imaging  Network  (ACRIN)  through  a  grant 
mechanism.
The NLST used a 1:1 ratio to randomly assign individuals to 
receive  either  three  annual  computerized  tomography  or  three 
annual chest radiograph screens, with follow-up for outcomes for 
at least 5 years after randomization. Entry criteria, as described 
previously  in  detail  (10),  required  subjects  to  be  aged  between   
55 and 74 years and to have a minimum of 30 pack-years of ciga-
rette smoking history at the time of random assignment. Former 
smokers were required to have quit within 15 years of random   
assignment.  Current  smokers  were  defined  as  those  who  still 
smoked  cigarettes  regularly.  Recruitment  was  conducted  by  33 
medical institutions across the United States, with the goal of en-
rolling a sample representative of the US population at high risk of 
lung cancer death. Accrual was completed in April 2004, and par-
ticipants  currently  are  being  followed  to  evaluate  clinical  out-
comes,  including  vital  status  and  cause  of  death.  The  primary 
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  Background  The National Lung Screening Trial (NLST), a randomized study conducted at 33 US sites, is comparing lung 
cancer mortality among persons screened with reduced dose helical computerized tomography and among 
persons screened with chest radiograph. In this article, we present characteristics of the study population.
  Methods  Eligible participants were aged 55–74 years and were current or former smokers with a cigarette smoking his-
tory of at least 30 pack-years. Randomization was stratified by site, sex, and age. To assess representativeness 
of the study population, demographic characteristics of individuals from the general population who met NLST 
age and smoking history inclusion criteria were obtained from the Tobacco Use Supplement of the US Census 
Bureau Current Population Surveys.
  Results  The NLST enrolled 53 456 persons, with 26 733 randomly assigned to chest radiograph screening and 26 723 to 
computerized tomography screening. Characteristics of the participants were as follows: 31 533 (59%) were men, 
39 234 (73%) were younger than 65 years, 25 779 (48%) were current smokers, and 16 839 (32%) had a college or 
higher degree. Median cigarette exposure was 48 pack-years. Among Tobacco Use Supplement respondents who 
met NLST age and smoking history criteria, 59% were men, 65% were younger than 65 years, and 57% were current 
smokers. Median cigarette exposure among this group was 47 pack-years, and 14% had a college degree or higher.
 Conclusion  The NLST cohort has a distribution of sex and pack-year history that is similar to the component of the general 
US population that meets the major NLST eligibility criteria; however, NLST participants are younger, better 
educated, and less likely to be current smokers.
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endpoint of the NLST is lung cancer–specific mortality, and the 
trial has 90% power to detect a 20% mortality reduction in the 
computerized  tomography  arm  relative  to  the  chest  radiograph 
arm. Conclusive results for the primary endpoint are expected by 
mid-2011. The purpose of this article was to provide a detailed 
description of demographic, medical, and other characteristics of 
the NLST study population at the time of randomization.
Participants and Methods
The study was performed after approval by an institutional review 
board at each institution. Written informed consent was obtained 
from each subject.
Recruitment Strategies
Thirty-three  medical  institutions  participated  in  the  NLST 
(Clinicaltrials.gov,  NCT  00047385)  and  were  widely  dispersed 
throughout the United States (Figure 1 and Table 1). Participants 
were recruited by use of techniques that included targeted mail-
ings, local radio and newspaper advertisements, outreach including 
health fairs and presentations to unions and community groups, 
NCI and institutional Web sites, Internet-based advertising that 
listed toll-free numbers for the NCI’s Cancer Information Service, 
and  public  service  television  and  radio  announcements.  Local 
chapters  of  the  American  Cancer  Society  provided  recruitment 
support to many sites.
Minority Recruitment Strategies
Targeted minority recruitment plans were implemented at specific 
sites  on  the  basis  of  regional  demographic  data  and  site-specific 
strategies and included advertising at minority-focused conferences 
and events; direct mailings to minority communities; advertisements 
in local minority newspapers and on radio stations; use of minority 
“ambassadors” in community settings; dissemination of information 
on NLST by minority health-care providers; translation of trial-
related  materials  into  Spanish,  Chinese  dialects,  and  Farsi;  and 
provision  of  minority  press  kits  to  more  than  70  media  outlets. 
These  efforts  were  assisted  through  collaboration  with  the  NCI 
Cancer  Information  Service  Partnership  Program,  the  American 
Public Health Association’s Black Caucus of Health Workers, the 
NCI Spirit of Eagles Program, and the American Cancer Society.
Enrollment and Randomization of Participants
Study eligibility, including smoking history, was assessed through 
use of an eligibility screener, which was administered by telephone 
or in-person by trained interviewers. The eligibility screener was 
designed to allow for the computation of number of pack-years of 
cigarettes smoked and determination of whether subjects smoked 
within the past 15 years. Randomization occurred after data coor-
dinating centers confirmed that eligibility criteria had been met   
for a given individual; participants were then assigned to either   
the computerized tomography arm or chest radiograph arm in a 
1:1 ratio, stratifying by site, sex, and 5-year age group. Stratified 
randomization was accomplished by use of a block size of six or 
eight, with block size chosen at random. At the time of the enroll-
ment, participants filled out a questionnaire that contained ques-
tions on personal history of selected diseases, including respiratory 
diseases, cardiovascular diseases, stroke, and diabetes; family his-
tory of lung cancer; occupational history (jobs and industries either 
previously demonstrated or thought to be associated with increased 
risk of lung disease or lung cancer); weight and height; and demo-
graphic factors such as education and marital status. Compliance 
with questionnaire completion was 99.6% (53 267 of the 53 456 
participants) and was similar in both study arms.
Comparison Between the NLST Population and the 
General Population at Risk for Lung Cancer
To assess whether the NLST population was representative of the 
overall US population that was likely to be eligible for the trial, we 
used the Census  Department’s Tobacco Use Supplement of the 
Continuing  Population  Survey  for  2002–2004,  the  years  corre-
sponding to the period of NLST enrollment (11). The Tobacco 
Use Supplement contains questions about respondents’ past and 
present cigarette smoking, captures demographic information and 
other behavioral data, and contains information on a scientifically 
selected, nationally representative sample of approximately 240 000 
individuals.  Using  the  responses  to  Tobacco  Use  Supplement 
questions, we identified the subset of respondents who were aged 
55–74 years, had smoking history of at least 30 pack-years, and 
were  either  current  smokers  or  former  smokers  who  had  quit 
within the past 15 years. For this subset of 9090 individuals, we 
CONTEXT AND CAVEATS
Prior knowledge
The National Lung Screening Trial (NLST) is comparing lung can-
cer  mortality  among  persons  who  were  randomly  assigned  to 
screening with reduced dose helical computerized tomography or 
with chest x-ray.
Study design
Baseline demographic characteristics of individuals from the NLST 
were compared with those from the general population who met 
NLST age and smoking history inclusion criteria who were selected 
from  the  Tobacco  Use  Supplement  of  the  US  Census  Bureau 
Current Population Surveys. Eligible participants were aged 55–74 
years and were current or former smokers with a cigarette smoking 
history of at least 30 pack-years.
Contribution
Characteristics of the NLST participants were compared with those 
of a group representing the general population. In both popula-
tions, 59% were men. NLST participants were younger than those 
from  the  general  population,  fewer  were  current  smokers,  and 
more than twice as many had a college degree or higher.
Implications
The proportion of men and pack-year history were similar between 
NLST participants and the groups from the general US population 
that met the major NLST eligibility criteria. There were differences 
between the two groups on age, education, and smoking status.
Limitations
Data  on  personal,  family,  and  occupational  history  were  self-
reported and collected with a self-administered questionnaire.
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evaluated  the  distribution  of  age,  sex,  race,  Hispanic  ethnicity, 
marital status, and education, as well as smoking status (current vs 
former)  and  pack-years  of  cigarettes  smoked.  We  compared 
distributions of participants identified through the Tobacco Use 
Supplement with those of NLST participants.
Results
Study Accrual
NLST enrollment began on September 18, 2002 and was completed 
on April 26, 2004, 4 months before the targeted completion date. 
The  study  enrolled  53 456  individuals,  with  9016  subjects  being 
enrolled in 2002, 38 584 in 2003, and 5856 in 2004. Of the 53 456 
participants, 34 614 (65%) were accrued from Lung Screening Study 
sites and 18 842 (35%) from ACRIN sites (Table 1). As of November 
30, 2009, 192 enrolled persons who were thought to be eligible at 
the  time  of  randomization  were  determined  to  be  ineligible. 
Common reasons for ineligibility included computerized tomogra-
phy within 18 months before enrollment (n = 68), nonsmoker or quit 
more than 15 years before randomization (n = 23), participation in 
another cancer screening trial (n = 28), recent antibiotic use (n = 17), 
insufficient pack-years (n = 12), diagnosis of cancer in the 5 years 
before randomization (n = 14), and age older or younger than the 
required range (n = 12). These randomized but ineligible subjects are 
included in the study and in the current analysis.
Comparison of the Lung Screening Study and ACRIN study 
populations showed that the two groups were quite similar with 
respect  to  demographics:  13 630  (72%)  of  18 842  ACRIN  and 
25 604  (74%)  of  34 614  Lung  Screening  Study  subjects  were 
younger  than  65  years  and  8440  (45%)  of  ACRIN  and  13 483 
(39%) of Lung Screening Study subjects were women. A total of 
9514 (50%) of ACRIN and 16 265 (47%) of Lung Screening Study 
subjects were current smokers.
Demographic Characteristics
Of the total of 53 456 participants, 26 733 were randomly assigned 
to chest radiograph screening and 26 723 were randomly assigned to 
computerized tomography. The distribution of sex and age by study 
arm is shown in Table 2. A total of 31 533 (59%) of participants 
were men and 39 234 (73%) were younger than 65 years. Mean age 
of the entire cohort was 61.4 years (standard deviation = 5.0 years). 
Median  age  was  60  years  (interquartile  range  =  57–65  years). 
Because randomization was stratified by sex and 5-year age group, 
the participant numbers are virtually identical within these cate-
gories across study arms.
The distribution of race, Hispanic or Latino ethnicity, marital 
status, educational status, and body mass index by study arm is 
shown in Table 2. The distribution of these characteristics was 
similar across study arms. Most individuals (48 549 or 91%) in the 
cohort were white, 2378 (4.4%) were black, and 935 (1.7%) were 
of Hispanic or Latino ethnicity. Only 3252 (6%) did not have a 
high school degree, and 16 839 (approximately 32%) had at least a 
college degree. A total of 15 017 (28%) of the NLST subjects were 
obese by Center for Disease Control criteria (ie, body mass index ≥ 
30 kg/m
2).
Smoking History
Details  of  smoking  history  in  these  subjects  are  presented  in 
Tables 2 and 3. Smoking patterns were similar across study arms. 
A total of 27 677 (52%) of the cohort of 53 456 participants were 
former smokers and 25 779 (48%) were current smokers. Among 
the 27 677 former smokers, 7891 (29%) reported quitting within 4 
years of study entry. Smoking status showed a strong age trend, 
with  the  percentage  of  current  smokers  decreasing  from  54% 
among those aged 55–59 years to 47% among those aged 60–64 
years, 41% among those aged 65–69 years, and 38% among those 
aged 70–74 years. Median pack-year history of smoking was sim-
ilar for current smokers (48 pack-years) and former smokers (50 
pack-years). Duration of smoking was similar for current smokers 
and for former smokers, with a median of 43 years for both arms.
Occupational Exposure and Medical History
Information  concerning  work  experience  in  occupations  and 
industries thought to increase risk of lung disease or lung cancer is 
Figure  1.  Map  of  the  United  States 
showing  National  Lung  Screening  Trial 
screening centers. The size of the bubble 
surrounding each site indicates the rela-
tive number of participants enrolled at the 
site.  The  number  adjacent  to  each  site 
corresponds  to  the  number  assigned  to 
the site in Table 1.1774   Articles | JNCI  Vol. 102, Issue 23  |  December 1, 2010
shown in Table 4. Approximately 28% of participants in each arm 
reported working in at least one of the listed industries and/or 
occupations that have been associated with increased risk of lung 
disease or cancer. The most common of these industries and occu-
pations  were  farming  (10.7%  or  5699  participants),  chemicals   
or  plastics  manufacturing  (6.2%  or  3317  participants),  welding 
(5.6% or 2975 participants), and painting (5.3% or 2813 partici-
pants). Approximately 5% of participants had worked with asbes-
tos. The median duration of employment was 10 years or less for 
each industry and occupation, except for firefighting (which was 12 
years  in  computerized  tomography  arm  and  11  years  in  chest 
radiograph arm). Work history differed by sex, with 11 957 (38%) 
of the 31 533 men vs 3048 (14%) of the 21 923 women reporting a 
work history in any of the listed occupations.
The history of selected diseases, including respiratory, cardio-
vascular and malignant diseases, as well as family history of cancer, 
is presented in Table 5. Results were similar across arms. With 
respect to respiratory diseases, 9326 (17%) of the 53 456 subjects 
reported  a  history  of  chronic  obstructive  pulmonary  disease 
(COPD),  chronic  bronchitis,  or  emphysema  and  approximately 
22% in each arm reported a history of pneumonia. A history of 
cardiovascular  disease  was  quite  common,  with  18 930  (35%) 
reporting a history of hypertension and 6797 (13%) reporting a 
history of heart disease or heart attack; in addition, 5174 (10%) 
reported a history of diabetes.
Data on family history of lung cancer were reported by each 
participant (Table 5). A family history of lung cancer (in a parent, 
sibling, or child) was reported by 11 621 (22%) of the 53 546 sub-
jects, with 1748 (3%) reporting two or more relatives with a lung 
cancer history. This prevalence was similar in the two study arms.
Characteristics  of  the  NLST  population  as  compared  with 
those of the overall NLST-eligible US population as measured 
with the Tobacco Use Supplement are shown in Table 6. The 
NLST population was younger than the US eligible population 
(73% were younger than 65 years vs 65%, respectively), but the 
populations were similar in terms of sex (59% of both populations 
were men). The proportions of blacks and Hispanics were roughly 
similar in the two populations. NLST subjects were substantially 
more educated, with the percentage having less than a high school 
education being 6% in the NLST cohort and 21% in the Tobacco 
Table 1. National Lung Screening Trial accrual data by study group and screening center*
Study group Screening center Location Accrual, No. of participants
ACRIN 1. Beth Israel Deaconess Medical Center Boston, MA 629
2. Brigham and Women’s Hospital Boston, MA 540
3. Brown University, Rhode Island Hospital Providence, RI 827
4. The Cancer Institute of New Jersey New Brunswick, NJ 88
5. Dartmouth-Hitchcock Medical Center Lebanon, NH 575
6. Emory University Atlanta, GA 1231
7. Jewish Hospital Rudd Heart and Lung Center Louisville, KY 1971
8. Johns Hopkins University Baltimore, MD 1670
9. Mayo Clinic, Jacksonville Jacksonville, FL 288
10. Mayo Clinic, Rochester Rochester, MN 1183
11. Medical University of South Carolina Charlestown, SC 578
12. Moffitt Cancer Center Tampa, FL 787
13. Northwestern University Chicago, IL 426
14. Ochsner Medical Center New Orleans, LA 504
15. St. Elizabeth Health Center Youngstown, OH 1046
16. University of California, Los Angeles Los Angeles, CA 1587
17. University of California, San Diego San Diego, CA 155
18. University of Iowa Iowa City, IA 1154
19. University of Michigan Medical Center Ann Arbor, MI 857
20. University of Pennsylvania Philadelphia, PA 386
21. University of Texas M.D. Anderson Cancer Center Houston, TX 782
22. Vanderbilt University Nashville, TN 465
23. Wake Forest University Winston-Salem, NC 1113
Total   18 842
LSS 24. Georgetown University Medical Center Washington, DC 1827
25. Henry Ford Health System Detroit, MI 3395
26. Marshfield Clinic Research Foundation Marshfield, WI 2520
27. Pacific Health Research & Education Institute† Honolulu, HI 2359
28. University of Alabama at Birmingham Birmingham, AL 5052
29. University of Colorado Denver Aurora, CO 3743
30. University of Minnesota School of Public Health Minneapolis, MN 6618
31. University of Pittsburgh Medical Center Pittsburgh, PA 2177
32. University of Utah Health Sciences Center Salt Lake City, UT 3159
33. Washington University School of Medicine St Louis, MO 3764
Total   34 614
Total     53 456
*  ACRIN = American College of Radiology Imaging Network; LSS = Lung Screening Study.
†  Formerly known as Pacific Health Research Institute.jnci.oxfordjournals.org    JNCI | Articles 1775
Table 2. Demographic factors and baseline smoking status of participants in the National Lung Screening Trial by screening arm*
Characteristic Spiral CT, No. (%) X-ray, No. (%) Total, No. (%)
Total 26 723 (100.0) 26 733 (100.0) 53 456 (100.0)
Age at randomization    
  <55,† y 2 (0.0) 3 (0.0) 5 (0.0)
  55–59 y 11 440 (42.8) 11 421 (42.7) 22 861 (42.8)
  60–64 y 8170 (30.6) 8198 (30.7) 16 368 (30.6)
  65–69 y 4756 (17.8) 4762 (17.8) 9518 (17.8)
  70–74 y 2352 (8.8) 2345 (8.8) 4697 (8.8)
  >74,† y 1 (0.0) 3 (0.0) 4 (0.0)
  Missing 2 (0.0) 1 (0.0) 3 (0.0)
Sex    
  Male 15 770 (59.0) 15 763 (59.0) 31 533 (59.0)
  Female 10 953 (41.0) 10 970 (41.0) 21 923 (41.0)
Race    
  White 24 289 (90.9) 24 260 (90.7) 48 549 (90.8)
  Black or African American 1196 (4.5) 1182 (4.4) 2378 (4.4)
  Asian 559 (2.1) 536 (2.0) 1095 (2.0)
  American Indian or Alaskan Native 92 (0.3) 98 (0.4) 190 (0.4)
  Native Hawaiian or other Pacific Islander 91 (0.3) 102 (0.4) 193 (0.4)
  More than one race 333 (1.2) 346 (1.3) 679 (1.3)
  Missing 163 (0.6) 209 (0.8) 372 (0.7)
Hispanic ethnicity    
  Hispanic or Latino 479 (1.8) 456 (1.7) 935 (1.7)
  Neither Hispanic nor Latino 26 080 (97.6) 26 040 (97.4) 52 120 (97.5)
  Missing 164 (0.6) 237 (0.9) 401 (0.8)
Marital status    
  Never married 1255 (4.7) 1203 (4.5) 2458 (4.6)
  Married or living as married 17 815 (66.7) 17 775 (66.5) 35 590 (66.6)
  Widowed 1985 (7.4) 1982 (7.4) 3967 (7.4)
  Separated 338 (1.3) 330 (1.2) 668 (1.2)
  Divorced 5194 (19.4) 5238 (19.6) 10 432 (19.5)
  Missing 136 (0.5) 205 (0.8) 341 (0.6)
Educational status    
  ≤8th grade 363 (1.4) 392 (1.5) 755 (1.4)
  9th–11th grade 1279 (4.8) 1218 (4.6) 2497 (4.7)
  High school graduate or GED 6274 (23.5) 6437 (24.1) 12 711 (23.8)
  Post–high school training, excluding college 3768 (14.1) 3726 (13.9) 7494 (14.0)
  Associate’s degree or some college 6262 (23.4) 6152 (23.0) 12 414 (23.2)
  Bachelor’s degree 4506 (16.9) 4442 (16.6) 8948 (16.7)
  Graduate school 3927 (14.7) 3964 (14.8) 7891 (14.8)
  Other 227 (0.8) 241 (0.9) 468 (0.9)
  Missing 117 (0.4) 161 (0.6) 278 (0.5)
CDC categories    
  Underweight (<18.5 kg/m2) 245 (0.9) 252 (0.9) 497 (0.9)
  Normal (18.5–24.9 kg/m
2) 7517 (28.1) 7331 (27.4) 14 848 (27.8)
  Overweight (25–29.9 kg/m
2) 11 265 (42.2) 11 491 (43.0) 22 756 (42.6)
  Obese (≥30 kg/m2) 7555 (28.3) 7462 (27.9) 15 017 (28.1)
  Missing 141 (0.5) 197 (0.7) 338 (0.6)
Smoking status    
  Current smokers 12 869 (48.2) 12 910 (48.3) 25 779 (48.2)
  Former smokers 13 854 (51.8) 13 823 (51.7) 27 677 (51.8)
    Quit within 4 y of study entry 3944 (14.8) 3947 (14.8) 7891 (14.8)
    Quit 4–9.9 y before study entry 4598 (17.2) 4645 (17.4) 9243 (17.3)
    Quit 10–15 y before study entry 5257 (19.7) 5165 (19.3) 10 422 (19.5)
    Missing 55 (0.2) 66 (0.2) 121 (0.2)
*  CDC = Center for Disease Control; CT = computerized tomography; GED = General Equivalency Diploma.
†  Participants in the age groups of younger than 55 years and older than 74 years were ineligible.
Use Supplement cohort and the percentage with at least a college 
degree being 32% in the NLST cohort and 14% in the Tobacco 
Use Supplement cohort. NLST subjects were also slightly more 
likely to be married (67% vs 60%, respectively). Geographically, 
the NLST cohort, compared with the Tobacco Use Supplement 
cohort, had a greater proportion of Midwesterners (39% vs 29%, 
respectively) and smaller percentages of Southerners (24% vs 33%, 
respectively)  and  Northeasterners  (16%  vs  21%,  respectively). 
With respect to smoking history, subjects in the NLST cohort 
were less likely to be current smokers than those in the Tobacco 1776   Articles | JNCI  Vol. 102, Issue 23  |  December 1, 2010
Use  Supplement  cohort  (48%  vs  57%,  respectively),  but  both 
cohorts  had  similar  median  pack-years  of  cigarette  smoking   
(48 pack-years vs 47 pack-years, respectively).
Discussion
The validity of a randomized controlled trial rests on the ability of 
the randomization process to produce study arms that are similar 
with regard to characteristics that are or could be related to the 
outcome of interest. Our analysis of the baseline characteristics of 
the NLST population has demonstrated that the randomization 
process in NLST produced two very similar groups of participants 
(Tables 2–5). For example, the distributions of smoking character-
istics, past occupational exposure, disease history, and family his-
tory of lung cancer were essentially indistinguishable between the 
two  study  arms.  Demographically,  the  baseline  age  and  sex 
distributions in the two arms were virtually identical because of 
stratified  randomization  on  these  factors.  In  addition,  the  race, 
Table 4. Work experience of participants in the National Lung Screening Trial by screening arm*
Type of work
Spiral CT X-ray Total
No. (%) ME, y No. (%) ME, y No. (%) ME, y
Asbestos work 1238 (4.6) 8.0 1288 (4.8) 10.0 2526 (4.7) 9.0
Baking 603 (2.3) 3.0 551 (2.1) 3.0 1154 (2.2) 3.0
Butchering/meat packing 572 (2.1) 3.0 593 (2.2) 4.0 1165 (2.2) 3.0
Chemicals or plastics manufacturing 1642 (6.1) 8.0 1675 (6.3) 7.0 3317 (6.2) 8.0
Coal mining 169 (0.6) 8.0 162 (0.6) 9.0 331 (0.6) 8.0
Cotton or jute processing 194 (0.7) 4.0 201 (0.8) 4.0 395 (0.7) 4.0
Farming 2837 (10.6) 10.0 2862 (10.7) 10.0 5699 (10.7) 10.0
Firefighting 477 (1.8) 12.0 513 (1.9) 11.0 990 (1.9) 12.0
Flour, feed, or grain milling 290 (1.1) 4.0 297 (1.1) 4.0 587 (1.1) 4.0
Foundry or steel milling 1159 (4.3) 6.0 1089 (4.1) 5.0 2248 (4.2) 5.0
Hard rock mining 205 (0.8) 5.0 213 (0.8) 5.0 418 (0.8) 5.0
Painting 1382 (5.2) 5.0 1431 (5.4) 5.0 2813 (5.3) 5.0
Sandblasting 456 (1.7) 4.0 457 (1.7) 4.0 913 (1.7) 4.0
Welding 1505 (5.6) 10.0 1470 (5.5) 10.0 2975 (5.6) 10.0
Any of the above occupations 7448 (27.9)   7557 (28.3)   15 005 (28.1)
*  CT = computerized tomography; ME = median exposure.
Table 3. Baseline smoking frequency per pack-year history of participants in the National Lung Screening Trial by study arm*
Screening group  
and characteristic
No. of pack-years smoked No. of cigarettes smoked per day No. of years of smoking
Current  
smoker
Former  
smoker
Entire  
cohort
Current  
smoker
Former  
smoker
Entire  
cohort
Current  
smoker
Former  
smoker
Entire  
cohort
Spiral CT                
  No. 12 869 13 854 26 723 12 869 13 854 26 723 12 868 13 853 26 721
  Mean 55.52 56.52 56.04 25.98 30.77 28.47 43.44 42.74 43.08
  Minimum 18 21 18 10 10 10 13 12 12
  First quartile 40.0 38.8 39.0 20.0 20.0 20.0 40.0 38.0 39.0
  Median 48.0 49.0 48.0 20.0 30.0 25.0 43.0 43.0 43.0
  Third quartile 66.0 67.5 66.0 30.0 40.0 35.0 47.0 48.0 47.0
  Maximum 235 295 295 100 140 140 67 69 69
X-ray                
  No. 12 910 13 823 26 733 12 910 13 823 26 733 12 910 13 823 26 733
  Mean 55.30 56.51 55.93 25.90 30.76 28.41 43.41 42.77 43.08
  Minimum 25 15 15 10 10 10 16 10 10
  First quartile 40.0 38.0 39.0 20.0 20.0 20.0 40.0 38.0 39.0
  Median 48.0 49.5 48.0 20.0 30.0 25.0 43.0 43.0 43.0
  Third quartile 64.5 68.0 66.3 30.0 40.0 35.0 47.0 48.0 47.0
  Maximum 412 568 568 201 258 258 70 69 70
Total                
  No. 25 779 27 677 53 456 25 779 27 677 53 456 25 778 27 676 53 454
  Mean 55.41 56.52 55.98 25.94 30.77 28.44 43.43 42.75 43.08
  Minimum 18 15 15 10 10 10 13 10 10
  First quartile 40.0 38.3 39.0 20.0 20.0 20.0 40.0 38.0 39.0
  Median 48.0 49.5 48.0 20.0 30.0 25.0 43.0 43.0 43.0
  Third quartile 65.0 68.0 66.0 30.0 40.0 35.0 47.0 48.0 47.0
  Maximum 412 568 568 201 258 258 70 69 70
*  CT = computerized tomography.jnci.oxfordjournals.org    JNCI | Articles 1777
ethnicity, education, and marital status profiles were similar in the 
two arms.
It  is  useful  to  evaluate  whether  the  results  of  a  randomized 
controlled trial are generalizable to the population from which the 
study participants were drawn, also known as the “base population.” 
Generalizability  can  be  assessed  in  part  by  examining  whether 
certain characteristics of the study sample are distributed similarly 
to  those  in  the  base  population.  To  assess  generalizability,  we 
compared distributions of characteristics that are known or sus-
pected to affect risk of lung cancer–specific death among NLST 
participants  with  those  from  respondents  to  the  Tobacco  Use 
Supplement of the Current Population Survey from the Census 
Department who met the NLST age and smoking eligibility crite-
ria (11). For several key factors, including sex, race, ethnicity, and 
pack-years of smoking, the NLST and Tobacco Use Supplement 
populations were quite similar. The similarity of the percentages 
of black and Hispanic subjects indicated that targeted minority 
recruitment efforts were quite successful. Although there was no 
specific criterion in NLST to ensure that screening centers were 
selected to ensure geographic representativeness, the distribution 
of NLST subjects across the four regions of the country was gen-
erally reflective of the eligible population, with a modest over-
weighting of the Midwest and slight underweighting of the other 
regions. There is no reason to believe, however, that these minor 
geographic differences will affect findings in such a manner that 
results are not able to be generalized.
Research participants are often healthier than those to whom 
study results are to be generalized. Such a phenomenon can bias 
study  outcomes  if  the  fact  that  study  participants  are  healthier 
results in a different outcome than would have been observed if the 
health of participants was similar to that of the base population. 
Distribution of certain characteristics did suggest that the NLST 
Table 5. History of selected respiratory and cardiovascular diseases, selected malignancies, and family history of lung cancer, among 
participants in the National Lung Screening Trial by screening arm*
Disease Spiral CT, No. (%) X-ray, No. (%) Total, No. (%)
Respiratory and cardiovascular disease    
  Asbestosis 276 (1.0) 257 (1.0) 533 (1.0)
  Asthma first diagnosed as an adult 1666 (6.2) 1653 (6.2) 3319 (6.2)
  Asthma first diagnosed as a child 935 (3.5) 974 (3.6) 1909 (3.6)
  Bronchiectasis 854 (3.2) 901 (3.4) 1755 (3.3)
  Chronic bronchitis 2592 (9.7) 2545 (9.5) 5137 (9.6)
  COPD 1347 (5.0) 1343 (5.0) 2690 (5.0)
  Emphysema 2056 (7.7) 2037 (7.6) 4093 (7.7)
  Chronic bronchitis, emphysema, or COPD 4674 (17.5) 4652 (17.4) 9326 (17.4)
  Diabetes 2594 (9.7) 2580 (9.7) 5174 (9.7)
  Fibrosis of the lung 70 (0.3) 58 (0.2) 128 (0.2)
  Heart disease or heart attack 3445 (12.9) 3352 (12.5) 6797 (12.7)
  Pneumonia 5930 (22.2) 5879 (22.0) 11 809 (22.1)
  Sarcoidosis 48 (0.2) 49 (0.2) 97 (0.2)
  Silicosis 30 (0.1) 27 (0.1) 57 (0.1)
  Tuberculosis 281 (1.1) 296 (1.1) 577 (1.1)
  Hypertension 9378 (35.1) 9552 (35.7) 18 930 (35.4)
  Stroke 753 (2.8) 759 (2.8) 1512 (2.8)
  Any of the above diseases 17 567 (65.7) 17 552 (65.7) 35 119 (65.7)
Malignancies    
  Bladder cancer 112 (0.4) 128 (0.5) 240 (0.4)
  Breast cancer† 352 (3.2) 396 (3.6) 748 (3.4)
  Cervical cancer† 364 (3.3) 404 (3.7) 768 (3.5)
  Breast or cervical cancer† 703 (6.4) 783 (7.1) 1486 (6.8)
  Colorectal cancer 111 (0.4) 119 (0.4) 230 (0.4)
  Esophageal cancer 12 (0.0) 8 (0.0) 20 (0.0)
  Kidney cancer 37 (0.1) 31 (0.1) 68 (0.1)
  Cancer of the larynx 20 (0.1) 26 (0.1) 46 (0.1)
  Nasal cancer 11 (0.0) 10 (0.0) 21 (0.0)
  Oral cancer 51 (0.2) 52 (0.2) 103 (0.2)
  Cancer of the pharynx 3 (0.0) 5 (0.0) 8 (0.0)
  Any head and neck cancer 82 (0.3) 89 (0.3) 171 (0.3)
  Pancreatic cancer 4 (0.0) 3 (0.0) 7 (0.0)
  Stomach cancer 12 (0.0) 15 (0.1) 27 (0.1)
  Thyroid cancer 36 (0.1) 47 (0.2) 83 (0.2)
  Any of the above cancers 1073 (4.0) 1194 (4.5) 2267 (4.2)
Family history of lung cancer
  Any first-degree relative‡ 5815 (21.8) 5806 (21.7) 11 621 (21.7)
  Two or more first-degree relatives 885 (3.3) 863 (3.2) 1748 (3.3)
*  COPD = chronic obstructive pulmonary disease; CT = computerized tomography.
†  Female participants only.
‡  A first-degree relative was defined as a parent, brother, sister, or children of an individual (National Cancer Institute—http://www.cancer.gov/dictionary/).1778   Articles | JNCI  Vol. 102, Issue 23  |  December 1, 2010
Table 6. Comparison of the National Lung Screening Trial (NLST) 
cohort with the NLST-eligible US population from the Tobacco 
Use Supplement (TUS) of the US Census Bureau Current 
Population Surveys*
Characteristic NLST TUS
Male, % 59.0 58.5
Age group, %  
  55–59 y 42.8 35.2
  60–64 y 30.6 29.3
  65–69 y 17.8 20.8
  70–74 y 8.8 14.7
Race/ethnicity, %  
  Black 4.4 5.5
  Hispanic or Latino, % 1.7 2.4
Education, %  
  Less than high school 6.1 21.3
  College degree or higher 31.5 14.4
Married, % 66.6 60.0
Current smoker, % 48.2 57.1
Median pack-years of cigarette smoking 48.0 47.0
US region, %  
  Northeast 16.3 21.1
  Midwest 39.2 28.8
  South 23.9 33.0
  West 20.6 17.2
*  Estimates were derived from the TUS of the US Bureau Current Population 
Survey for the years of NLST enrollment and were calculated by restricting 
the survey population to those respondents who met the NLST age and 
smoking eligibility criteria.
population might be healthier than the base population. For ex-
ample,  NLST  subjects  were  somewhat  younger  (73%  were 
younger than age 65 years vs 65% in the base population), were 
less likely to be current smokers (48% vs 57%, respectively), and 
were better educated (6% with less than a high school education vs 
21%, respectively). Whether these differences will affect the gen-
eralizability of study findings is unknown, but it seems unlikely 
that these relatively minor differences will result in a meaningful 
bias. Adjustments for such differences can be made through statis-
tical modeling. Other randomized prevention or screening trials, 
such  as  the  Prostate,  Lung,  Colorectal,  and  Ovarian  (PLCO) 
Cancer Screening Trial, have shown similar effects (12) (13). For 
example, in the PLCO Trial, the participants were better educated 
than the overall eligible population (12).
NLST data collected on smoking, family history of lung cancer, 
occupation and/or industry experience, and specific previous dis-
eases  will  be  used  for  epidemiological  analyses  of  lung  cancer 
incidence and mortality. The relationship of smoking, the stron-
gest risk factor, to lung cancer will be explored in great detail. 
Numerous inhalational exposures, either known or suspected to be 
associated with lung cancer (14), will also be investigated. However, 
details  of  inhalational  exposure  were  not  recorded.  More  than 
2500 of the NLST participants reported work-related exposure 
(median duration = 9 years) to asbestos, the environmental inhala-
tional exposure most definitively and strongly associated with lung 
cancer (15). This cohort is one of the largest groups of asbestos-
exposed subjects being actively followed for lung cancer (16,17) 
and will permit further evaluation of the well-known relationships 
among asbestos exposure, cigarette smoking, and lung cancer.
A  family  history  of  lung  cancer  is  also  associated  with  an 
increased risk of lung cancer. A systematic review of case–control 
and cohort studies (18) indicated that the presence of a relative 
with  lung  cancer  is  associated  with  a  statistically  significantly 
increased risk of lung cancer. Risk appears to be greatest in rela-
tives of persons diagnosed at a young age and in those with mul-
tiple affected family members. However, it remains unclear how 
much of this increased risk can be attributed to genetics and how 
much to the fact that relatives of smokers are more likely to be 
cigarette smokers or exposed to second-hand smoke. Twenty-two 
percent of NLST participants had a family history of lung cancer, 
and 3% had two or more first-degree relatives with lung cancer. 
This large cohort may permit further evaluation of the role of 
family history in the etiology of lung cancer. The NLST also will 
generate data to evaluate several medical conditions known to be 
associated with lung cancer. Among these conditions, the most 
salient is COPD (15), present by self-report (including reports of 
chronic  bronchitis  and  emphysema)  in  more  than  9300  NLST 
participants. The presence of emphysema (self-reported in almost 
4100 NLST participants) appears to be a greater risk factor for 
lung cancer than chronic airway obstruction (19,20). NLST ancil-
lary studies should assist in confirming the extent of increased risk 
that is associated with the diagnosis of COPD and with computer-
ized tomography–determined emphysema. Other risk factors for 
lung  cancer  present  in  the  NLST  cohort  include  asbestosis 
(reported by 533 participants), lung fibrosis (128 participants), sil-
icosis (57 participants), and history of head and neck cancer (171 
participants).
Limitations of the NLST as an epidemiological cohort include 
the fact that data on personal, family, and occupational history are 
self-reported and collected by use of a self-administered question-
naire.  However,  these  limitations  are  common  to  most  large 
studies of this type, and there was excellent participant compliance 
(99.6%) with completion of questionnaires.
We conclude that the NLST cohort is at high risk of lung can-
cer and is broadly reflective of the general US smoking population. 
The randomization process in the NLST resulted in study arms 
that have similar distributions of many known and suspected risk 
factors  for  lung  cancer.  In  addition  to  evaluating  the  relative 
impact of chest radiographic and chest computerized tomography 
screening on lung cancer–specific mortality, the NLST cohort can 
also be used to clarify other important questions regarding lung 
cancer epidemiology.
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